Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

95.5%

+9.0% vs industry average

Late-Stage Pipeline

59%

13 trials in Phase 3/4

Results Transparency

10%

2 of 21 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

12(57.1%)

Phase 2

5(23.8%)

Phase 1

3(14.3%)

Phase 4

1(4.8%)

21Total

Phase 3(12)

Phase 2(5)

Phase 1(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT01011335Phase 1Completed

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

Role: collaborator

NCT00218413Phase 2Completed

Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals

Role: lead

NCT00318383Phase 2Completed

Efficacy of NicVAX in Smokers Who Want to Quit Smoking

Role: collaborator

NCT00996034Phase 2Completed

Nicotine Vaccination and Nicotinic Receptor Occupancy

Role: collaborator

NCT00995033Phase 2Completed

Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)

Role: collaborator

NCT01304810Completed

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

Role: lead

NCT01375933Phase 3Completed

A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers

Role: lead

NCT00211991Phase 3Completed

Evaluation of Consistency of StaphVAX Manufacturing Lots

Role: lead

NCT00066989Phase 2Completed

Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates

Role: lead

NCT00063089Phase 1Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Role: lead

NCT00598325Phase 1Completed

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

Role: lead

NCT01178346Phase 3Completed

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Role: lead

NCT01102114Phase 3Completed

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

Role: lead

NCT00836199Phase 3Completed

NicVAX/Placebo as an Aid for Smoking Cessation

Role: lead

NCT00211978Phase 3Completed

EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

Role: lead

NCT00211939Phase 4Completed

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Role: lead

NCT00211926Phase 3Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Role: lead

NCT00130260Phase 3Terminated

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

Role: lead

NCT00211913Phase 3Completed

StaphVAX in Cardiovascular Surgery Patients

Role: lead

NCT00211900Phase 3Completed

Evaluation of Manufacturing Lot of StaphVAX

Role: lead